Treatment Outcome in Ocular Myasthenia Gravis

Update item information
Identifier 20200310_nanos_posters_260
Title Treatment Outcome in Ocular Myasthenia Gravis
Creator Melody Merati, Wayne Cornblath, Lina Nagia
Subject Myasthenia, Ocular Motility, Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid), Diagnostic Tests (ERG, VER, OCT, HRT, mfERG, etc), Eyelid & Adnexal Disease, Adult Strabismus with a Focus on Diplopia
Description Ocular Myasthenia Gravis (OMG) is an autoimmune disease that affects the neuro-muscular junction resulting in ptosis and/or diplopia without general or bulbar symptoms. OMG patients can suffer from disabling ocular symptoms. The outcome of treatment with OMG is poorly understood. Our aim is to assess outcome over time.
Relation is Part of NANOS Annual Meeting 2020: Poster Session II: Scientific Advancements
Contributor Primary Melody Merati
Contributor Secondary Wayne Cornblath, Lina Nagia
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2020-03
Format application/pdf
Source 2020 North American Neuro-Ophthalmology Society Annual Meeting
Rights Management Copyright 2020. For further information regarding the rights to this collection, please visit:
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Collection Neuro-ophthalmology Virtual Education Library: NOVEL
Language eng
ARK ark:/87278/s603420w
Setname ehsl_novel_nam
Date Created 2020-04-21
Date Modified 2020-05-28
ID 1542127
Reference URL
Back to Search Results